With the approval of idarucizumab, clinicians will have a more efficient tool to use for the reversal of dabigatran. Activate 4-factor prothrombin complex concentrate or recombinant factor VIIa to reverse the effects of the drug (off-label uses that made clinicians worry about thrombosis).Dialysis to assist the patient in clearing the drug (may be difficult to obtain access for dialysis catheters).Supportive therapy to allow the patient to clear the dabigatran (not a great option for a patient with life-threatening bleeding).When health care providers were previously faced with the need for urgent reversal of dabigatran, there were few options available, and none of them were ideal in life-threatening situations.
The FDA has granted accelerated approval for Boehringer Ingelheim’s idarucizumab (Praxbind), the first product specifically targeted to reverse the effects of dabigatran (Pradaxa).
0 kommentar(er)
